DiaMedica Therapeutics (DMAC) Receivables - Net (2017 - 2026)
DiaMedica Therapeutics' (DMAC) quarterly Receivables - Net came in at $301000.0 in Q1 2026, up 18.97% year-on-year from $253000.0 in Q1 2025, and up 16.67% quarter-over-quarter from $258000.0 in Q4 2025.
DiaMedica Therapeutics (DMAC) Receivables - Net (2017 - 2026) Analysis & Trends
DiaMedica Therapeutics' Receivables - Net history runs 10 years deep, the most recent figure standing at $301000.0 for Q1 2026.
- On a quarterly basis, Receivables - Net rose 18.97% year-over-year to $301000.0 in Q1 2026; TTM through Mar 2026 was $301000.0, a 18.97% increase from a year earlier, with the FY2025 full-year figure at $258000.0, up 9.32% from the prior year.
- Receivables - Net climbed to $301000.0 in Q1 2026 per DMAC's latest filing, from $258000.0 in the prior quarter.
- Across five years, Receivables - Net topped out at $399000.0 in Q1 2024 and bottomed at $57000.0 in Q1 2023.
- The 5-year median for Receivables - Net is $253000.0 (2025), against an average of $228588.2.
- Across the five-year window, Receivables - Net slumped 66.07% in 2023 and jumped 600.0% in 2024, its largest moves.
- Year by year, Receivables - Net stood at $82000.0 in 2022, then soared by 350.0% to $369000.0 in 2023, then slumped by 36.04% to $236000.0 in 2024, then grew by 9.32% to $258000.0 in 2025, then gained by 16.67% to $301000.0 in 2026.
- Per Business Quant, the three latest DMAC Receivables - Net figures stand at $301000.0 (Q1 2026), $258000.0 (Q4 2025), and $260000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | DiaMedica Therapeutics | 366.87 Mn | 366.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 301,000.00 |
| Mar 31, 2026 | 301,000.00 |
| Dec 31, 2025 | 258,000.00 |
| Dec 31, 2025 | 258,000.00 |
| Sep 30, 2025 | 260,000.00 |
| Sep 30, 2025 | 260,000.00 |
| Jun 30, 2025 | 161,000.00 |
| Jun 30, 2025 | 161,000.00 |
| Mar 31, 2025 | 253,000.00 |
| Mar 31, 2025 | 253,000.00 |
| Dec 31, 2024 | 236,000.00 |
| Dec 31, 2024 | 236,000.00 |
| Sep 30, 2024 | 290,000.00 |
| Sep 30, 2024 | 290,000.00 |
| Jun 30, 2024 | 391,000.00 |
| Jun 30, 2024 | 391,000.00 |
| Mar 31, 2024 | 399,000.00 |
| Mar 31, 2024 | 399,000.00 |
| Dec 31, 2023 | 369,000.00 |
| Dec 31, 2023 | 369,000.00 |